denkapparat Operations GmbH Purchases New Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

denkapparat Operations GmbH acquired a new stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 18,204 shares of the biopharmaceutical company’s stock, valued at approximately $171,000.

Several other hedge funds also recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its position in shares of Amicus Therapeutics by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 29,258,963 shares of the biopharmaceutical company’s stock worth $275,619,000 after purchasing an additional 458,143 shares during the last quarter. Wellington Management Group LLP raised its stake in Amicus Therapeutics by 13.5% during the third quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company’s stock valued at $255,936,000 after buying an additional 2,856,101 shares in the last quarter. Geode Capital Management LLC raised its stake in Amicus Therapeutics by 1.2% during the third quarter. Geode Capital Management LLC now owns 6,599,871 shares of the biopharmaceutical company’s stock valued at $70,499,000 after buying an additional 80,926 shares in the last quarter. Norges Bank bought a new position in Amicus Therapeutics during the 4th quarter worth approximately $29,033,000. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Amicus Therapeutics by 10.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,667,271 shares of the biopharmaceutical company’s stock worth $28,486,000 after acquiring an additional 242,672 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on FOLD shares. Morgan Stanley reissued an “equal weight” rating and set a $12.00 price target (down from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Cantor Fitzgerald restated an “overweight” rating and issued a $21.00 price target on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. StockNews.com downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, February 20th. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Finally, Wells Fargo & Company lowered their target price on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a report on Thursday, February 20th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.75.

Amicus Therapeutics Stock Performance

Shares of NASDAQ FOLD opened at $8.43 on Friday. Amicus Therapeutics, Inc. has a 12-month low of $8.36 and a 12-month high of $12.65. The company has a market cap of $2.59 billion, a PE ratio of -46.83, a P/E/G ratio of 1.51 and a beta of 0.69. The stock has a 50 day simple moving average of $9.28 and a 200-day simple moving average of $9.97. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.